home > pmps > summer 2008 > steadfast supplies
Pharmaceutical Manufacturing and Packing Sourcer

Steadfast Supplies

Can you tell me about Aesica and the company’s philosophy?

Aesica is a leading supplier of active pharmaceutical ingredients (APIs) and formulated products to the pharmaceutical industry. We are based in the UK and have three state-of-the-art manufacturing facilities. When we founded Aesica in 2004, we set out to bring something new to pharmaceutical manufacturing – an innovative, flexible and service-driven supplier of APIs, formulated products and custom synthesis solutions.

Since then we’ve more than trebled in size and built a customer base that includes the world’s largest pharmaceutical companies, leading generics manufacturers and emerging pharmaceutical companies. We also recently announced the appointment of Michael Staff as Vice President, Sales and Business Development, North America, marking the establishment of our commercial presence in North America.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Dr Robert Hardy, CEO, led the management team which founded Aesica through the MBO of BASF’s UK API business at Cramlington in August 2004. He has more than 20 years’ experience in the pharmaceutical industry. In 1983, he joined the BASF UK pharmaceutical manufacturing business when it was part of the Boots Company PLC. Robert has a BSc (Hons) and PhD from the University of Nottingham
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research


Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement